These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20671569)

  • 1. Complete resolution of very late stent thrombosis with systemic thrombolysis.
    Yiginer O; Kardesoglu E; Ozmen N; Aparci M; Cebeci BS
    J Cardiovasc Med (Hagerstown); 2011 Oct; 12(10):765-7. PubMed ID: 20671569
    [No Abstract]   [Full Text] [Related]  

  • 2. The lack of endothelization after drug-eluting stent implantation as a cause of fatal late stent thrombosis.
    Jakabcin J; Bystron M; Spacek R; Veselka J; Kvasnak M; Kala P; Malý J; Cervinka P
    J Thromb Thrombolysis; 2008 Oct; 26(2):154-8. PubMed ID: 17764000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiographic restenosis and clinical recurrence after sirolimus- and paclitaxel-eluting stent implantation.
    Vlaar PJ; Zijlstra F
    JACC Cardiovasc Interv; 2009 Aug; 2(8):776-8. PubMed ID: 19695547
    [No Abstract]   [Full Text] [Related]  

  • 4. Fibrinolytic therapy for very late stent thrombosis--is it a viable option?
    Hakeem A; Bhatti S; Arif I; Effat M; Cilingiroglu M
    Cardiovasc Revasc Med; 2010; 11(4):264.e13-5. PubMed ID: 20934665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial.
    Di Lorenzo E; De Luca G; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G
    JACC Cardiovasc Interv; 2009 Jun; 2(6):515-23. PubMed ID: 19539255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventional cardiology: Antithrombotic drug and stent choices in primary PCI.
    Menees DS; Bates ER
    Nat Rev Cardiol; 2011 Aug; 8(9):483-4. PubMed ID: 21826070
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term follow-up of drug-eluting stents placed in the setting of ST-segment elevation myocardial infarction.
    Ziada KM; Charnigo R; Moliterno DJ
    JACC Cardiovasc Interv; 2011 Jan; 4(1):39-41. PubMed ID: 21251627
    [No Abstract]   [Full Text] [Related]  

  • 8. Incomplete stent apposition: should we appose or oppose?
    Lindsey JB; Marso SP
    JACC Cardiovasc Interv; 2010 May; 3(5):495-7. PubMed ID: 20488405
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Kounis syndrome in everolimus-eluting stents and paclitaxel-eluting stents.
    Kounis NG; Giannopoulos S; Goudevenos JA
    Catheter Cardiovasc Interv; 2010 Dec; 76(7):1076-7; author reply 1078. PubMed ID: 21086494
    [No Abstract]   [Full Text] [Related]  

  • 11. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial.
    Lansky AJ; Ng VG; Mutlu H; Cristea E; Guiran JB; Midei M; Newman W; Sanz M; Sood P; Doostzadeh J; Su X; White R; Cao S; Sudhir K; Stone GW
    Catheter Cardiovasc Interv; 2009 Nov; 74(5):719-27. PubMed ID: 19530147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
    Vink MA; Dirksen MT; Suttorp MJ; Tijssen JG; van Etten J; Patterson MS; Slagboom T; Kiemeneij F; Laarman GJ
    JACC Cardiovasc Interv; 2011 Jan; 4(1):24-9. PubMed ID: 21251625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus- versus paclitaxel-eluting stents for unselected patients with coronary artery disease.
    Park SJ
    Catheter Cardiovasc Interv; 2011 Jan; 77(1):13-4. PubMed ID: 21181967
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of a double-coated paclitaxel-eluting coronary stent: the EUCATAX trial.
    Rodriguez AE; Vigo CF; Delacasa A; Mieres J; Fernandez-Pereira C; Bernardi V; Bettinoti M; Rodriguez-Granillo AM; Rodriguez-Granillo G; Santaera O; Curotto V; Rubilar B; Tronge J; Palacios IF; Antoniucci D;
    Catheter Cardiovasc Interv; 2011 Feb; 77(3):335-42. PubMed ID: 20824769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus: the LIPSIA Yukon trial.
    Desch S; Schloma D; Möbius-Winkler S; Erbs S; Gielen S; Linke A; Yu J; Lauer B; Kleinertz K; Dänschel W; Schuler G; Thiele H
    JACC Cardiovasc Interv; 2011 Apr; 4(4):452-9. PubMed ID: 21511226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Images in intervention. Optical coherence tomography findings in very late (4 years) paclitaxel-eluting stent thrombosis.
    Schinkel AF; Barlis P; van Beusekom HM; Serruys PW; Regar E
    JACC Cardiovasc Interv; 2008 Aug; 1(4):449-51. PubMed ID: 19463343
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial.
    Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE; Martinez EE;
    Catheter Cardiovasc Interv; 2009 Nov; 74(5):665-73. PubMed ID: 19670303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent.
    Grube E; Schofer J; Hauptmann KE; Nickenig G; Curzen N; Allocco DJ; Dawkins KD
    JACC Cardiovasc Interv; 2010 Apr; 3(4):431-8. PubMed ID: 20398872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Leon MB; Kandzari DE; Eisenstein EL; Anstrom KJ; Mauri L; Cutlip DE; Nikolsky E; O'Shaughnessy C; Overlie PA; Kirtane AJ; McLaurin BT; Solomon SL; Douglas JS; Popma JJ;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1208-18. PubMed ID: 20129547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.